🎤 Join our founder group to hear from firms like NEA on What it takes to raise a Series A?

Register
Get Started
Dina Chaya

Dina Chaya

Partner·OrbiMed

LinkedIn Bio source

Bio

Professional summary

Dina Chaya is a Partner on OrbiMed's Private Equity team, which she joined in 2023. She has invested in healthcare private equity and venture capital since 2001, with prior roles at Omega Funds, NeoMed, 3i and Index Ventures. Company board bios cite her successful investments including Imago BioSciences, CinCor Pharma, Wilson Therapeutics, EUSA Pharma, Endosense and Novexel.

Notable companies

Selected portfolio companies the partner has backed

ProVerum MedicalAlentis TherapeuticsImago BioSciencesCinCor PharmaWilson Therapeutics

Background

Career, education, and skills

Career history

  • OrbiMedPartner, Private Equity2023 – Present
  • Omega FundsInvestor
  • NeoMedInvestor
  • 3iInvestment professional
  • Index VenturesInvestment professional

Education

  • University of CambridgeB.A. in Natural Sciences
  • Paris VI UniversityPh.D. in Molecular and Cellular Biology

Other partners at OrbiMed

12 more profiles

View firm →
AT

Aditya Tolia

Private Equity Senior Analyst

OrbiMed

Private Equity Senior Analyst at OrbiMed with prior Investec and PwC banking experience.

Financial modelingHealthcare investingInvestment bankingM&APrivate equity
Alexis Megibow

Alexis Megibow

Private Equity Associate

OrbiMed

Private Equity Associate at OrbiMed.

Healthcare investingPrivate equityVenture capital
Ankesh Bhansali

Ankesh Bhansali

Managing Director

OrbiMed

OrbiMed Asia Managing Director focused on healthcare private equity.

Asia healthcareCapital marketsHealthcare deliveryHealthcare private equityM&APharmaceuticals
Arun Sadhanandham

Arun Sadhanandham

Managing Director

OrbiMed

OrbiMed Asia Managing Director investing in healthcare private equity.

Asia healthcareHealthcare deliveryHealthcare private equityInvestment bankingMedical devicesPharmaceuticals
BC

Brendan Weber, CFA

Principal

OrbiMed

Principal on OrbiMed's Credit & Royalty team focused on structured credit and royalty financings.

Healthcare creditMedical devicesPharmaceuticalsRoyalty-based financingStructured credit
CG

Carl Gordon

Managing Partner

OrbiMed

OrbiMed Managing Partner leading private equity and biotech company formation.

BiotechnologyBoard governanceCompany formationHealthcare private equityInnovative therapeuticsLife sciences
Carl L. Gordon

Carl L. Gordon

Managing Partner

OrbiMed

Carl L. Gordon is a Managing Partner at OrbiMed and leads the firm's private equity team.

Life-sciences private equityTherapeuticsVenture investing
CN

Carter Neild

Managing Partner

OrbiMed

OrbiMed Managing Partner focused on healthcare royalties and Asia private investments.

Asia private investmentsHealthcare private equityHealthcare royaltiesInvestment managementStructured healthcare finance
Clay Daniel DeMarcus

Clay Daniel DeMarcus

Principal

OrbiMed

Principal focused on medical technology and non-therapeutics venture investing.

Healthcare equity researchHealthcare investment bankingMedical technologyNon-therapeuticsVenture-stage investing
CS

Cooper Steputis

Private Equity / Venture Capital

OrbiMed

Healthcare private equity and venture investor with prior investment banking experience.

Healthcare venture capitalInvestment bankingMolecular biologyNeurosciencePrivate equity
Daniel Ying

Daniel Ying

Executive Director

OrbiMed

OrbiMed Asia Executive Director focused on pharma and biotech investments.

Asia healthcareBiotechnologyChina healthcare marketHealthcare private equityPharmaceuticals
David Bonita

David Bonita

General Partner

OrbiMed

OrbiMed General Partner and physician-investor in healthcare and therapeutics.

BiotechnologyBoard governanceHealthcare investingMedical devicesOncologyTherapeutics

See something out of date?

Suggest a correction — our team reviews every edit.

Improve this profile